Guillain-Barre syndrome following the first dose of SARS-CoV-2 vaccine, Oxford/AstraZeneca (ChAdOx1) / Síndrome de Guillain-Barre após a primeira dose da vacina contra a SRA-CoV-2, Oxford/AstraZeneca (ChAdOx1)
DOI:
https://doi.org/10.34119/bjhrv5n1-314Keywords:
ChAdOx, SARS-CoV-2 vaccine, Guillain-Barre syndrome, AstraZeneca.Abstract
In the United Kingdom, until 04/21, 6 patients with SGB after the ChAdOx1 were notified out of a total of 42.917 vaccinated, with an 80% reduction in hospitalization in the elderly after vaccination. Facts added to the global pandemic scenario, the vaccine remains necessary.
References
Keddie, S., Pakpoor, J., Mousele, C., Pipis, M., Machado, P. M., Foster, M., … Lunn, M. P. (2020). Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome. Brain. doi:10.1093/brain/awaa433.
Waheed S, Bayas A, Hindi F, et al. (February 18, 2021) Neurological Complications of COVID-19: Guillain-Barre Syndrome Following PfizerCOVID-19 Vaccine. Cureus 13(2): e13426. DOI 10.7759/cureus.13426.
Padroni, M., Mastrangelo, V., Asioli, G.M. et al. Guillain-Barré syndrome following COVID-19: new infection, old complication?. J Neurol 267, 1877–1879 (2020).
Keddie, S., Pakpoor, J., Mousele, C., Pipis, M., Machado, P. M., Foster, M., … Lunn, M. P. (2020). Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome. Brain. doi:10.1093/brain/awaa43.
